BofA analyst Joanna Gajuk raised the firm’s price target on BrightSpring Health (BTSG) to $41 from $38 and keeps a Buy rating on the shares after having hosted CEO Jon Rousseau and CFO Jennifer Phipps at the firm’s Home Care Conference. BrightSpring expects double-digit EBITDA growth again in 2026 and continues to target long term EBITDA growth in the 15% range, the analyst tells investors following the event.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services: Strategic Growth and Expansion Drive Promising Outlook
- BrightSpring Health initiated with an Outperform at William Blair
- BrightSpring Health Services: A Leader in Integrated Healthcare with Strong Growth Potential
- BrightSpring Health management to meet with KeyBanc
- Wells Fargo says CMS final rule positive for Pennant Group, BrightSpring Health